whatshot

RETA   $172.36  0.03% Market Closed

show_chart Advanced Chart of RETA
Last Events:

2023-08-09 Signal in Stochastic changed from bullish weakening to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: exit from the overbought zone.

2023-08-06 Trend pattern changed from восходящий клин to расходящийся клин с наклоном вверх.

2023-08-06 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-08-06 Trend Power changed from medium strength to almost flat.

2023-08-06 Trend changed from turning down to up and flat.

2023-08-05 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in overbought territory and it falls. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-08-02 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

Current temperature: 0.10
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 7
Target Price Mean 172.50
Mean unverified/preliminary 172.50 / 172.50
Target Price Low / High 172.00 / 173.00
Median / STD DEV 172.50 / 0.29
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi Buy Buy ActivelyBuy
macd None None None
stoch None None None
ma20 None ActivelyBuy None
ma50 None None None
ma100 Buy Buy None
Candlestick PatternSept. 25, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US75615P1030
ceo Mr. J. Warren Huff
Website https://www.reatapharma.com
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. As of September 26, 2023, Reata Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.